For Biohaven Ltd. (BHVN), a global clinical-stage biopharmaceutical company focused on developing life-changing therapies for rare and common diseases, the second half of 2026 could be a defining chapter, with pivotal data readouts poised to shape the future of its diverse pipeline.
At the core of this innovation are its novel platforms, MoDE and TRAP, designed to target the root causes of autoimmune diseases. MoDE targets a class of proteins implicated in disease pathogenesis, while TRAP selectively removes disease-causing proteins while leaving the rest of the immune system intact.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.